Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 9/2014

01-09-2014 | Resistant Hypertension (E Pimenta, Section Editor)

Cardiovascular and Renal Complications in Patients with Resistant Hypertension

Authors: Elizabeth S. Muxfeldt, Fabio de Souza, Victor S. Margallo, Gil F. Salles

Published in: Current Hypertension Reports | Issue 9/2014

Login to get access

Abstract

With an increased prevalence, resistant hypertension is recognized as an entity with a high cardiovascular morbidity and mortality. In a large cohort of patients with resistant hypertension, the crude incidence rate of total cardiovascular events reached 4.32 per 100 patient-years of follow-up (19.6 %), with a cardiovascular mortality of 8.3 % (incidence rate of 1.72 per 100 patient-years). Cardiovascular event rates are significantly higher in resistant hypertensives compared with non-resistant (18.0 % versus 13.5 %). In the same way, the prevalence of established cardiovascular and renal disease, as the asymptomatic organ damage (represented by left ventricular hypertrophy, carotid wall thickening, arterial stiffness, and microalbuminuria) is higher in these patients. Many studies have demonstrated a strong association between damage to these organs with higher blood pressure levels, the diagnosis of true resistant hypertension, and refractory hypertension. All efforts should be employed in order to control blood pressure and also to regress and/or prevent subclinical cardiovascular and renal damage. The focus should be on prevention of cardiovascular and renal complications, improving the prognosis of resistant hypertension.
Literature
1.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. Hypertension. 2003;42:1206–52.PubMedCrossRef
2.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Task Force Members. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.PubMedCrossRef
3.
Moser M, Roccella EJ. The Treatment of Hypertension: A Remarkable Success Story. J Clin Hypertens (Greenwich). 2013;15:88–91.CrossRef
4.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global Burden of Hypertension: Analysis of Worldwide Data. Lancet. 2005;365:217–23.PubMedCrossRef
5.
Lim SS, Vos T, Flaxman AD, et al. A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.PubMedCrossRef
6.•
Calhoun DA, Jones D, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19. The unique comprehensive guideline on resistant hypertension approach.PubMedCrossRef
7.
de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical Differences Between Resistant Hypertensives and Patients Treated and Controlled with Three or Less Drugs. J Hypertens. 2012;30:1211–6.PubMedCrossRef
8.
Muxfeldt ES, Salles GF. Pulse Pressure or Dipping Pattern: Which one is a Better Cardiovascular Risk Marker in Resistant Hypertension? J Hypertens. 2008;26:878–84.PubMedCrossRef
9.
Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated with Resistant Hypertension. Hypertension. 2011;58:811–7.PubMedCrossRef
10.
Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. ASCOT Investigators. Baseline Predictors of Resistant Hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a Risk Score to Identify Those at High-Risk. J Hypertens. 2011;29:2004–13.PubMedCrossRef
11.
Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High Prevalence of Cardiac and Extra- Cardiac Target Organ Damage in Refractory Hypertension. J Hypertens. 2001;19:2063–70.PubMedCrossRef
12.
Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-Four Hour Ambulatory Blood Pressure Monitoring Pattern of Resistant Hypertension. Blood Press Monit. 2003;8:181–5.PubMedCrossRef
13.
Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular Outcome in Treated Hypertensive Patients with Responder, Masked, False Resistant, and True Resistant Hypertension. Am J Hypertens. 2005;18:1422–8.PubMedCrossRef
14.
Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients. Circulation. 2012;125:1635–42.PubMedCentralPubMedCrossRef
15.••
Salles GF, Cardoso CR, Muxfeldt ES. Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension. Arch Intern Med. 2008;168:2340–6. Higher ambulatory blood pressure are important predictors of cardiovascular morbidity and mortality in a large cohort of RHT patients, but office BP has no prognostic importance.PubMedCrossRef
16.
Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory Hypertension: Definition, Prevalence, and Patient Characteristics. J Clin Hypertens. 2012;14:7–12.CrossRef
17.
Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K, et al. REACH Registry Investigators. Resistant Hypertension: A Frequent and Ominous Finding Among Hypertensive Patients with Atherothrombosis. Eur Heart J. 2013;34:1204–14.PubMedCrossRef
18.
Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, et al. Resistant Hypertension and Target Organ Damage. Hypertens Res. 2013;36:485–91.PubMedCrossRef
19.••
Calhoun DA, Booth 3rd JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension. 2014;63:451–8. New definition of refractory hypertension as (uncontrolled office BP using > 5 anti-hypertensive drugs), focusing a very higher cardiovascular risk compared with others RHT patients.PubMedCrossRef
20.
Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design. Neuroepidemiology. 2005;25:135–43.PubMedCrossRef
21.
Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients with Atherothrombosis. JAMA. 2006;295:180–9.PubMedCrossRef
22.
Parati G, Ochoa JE, Bilo G. Renal Sympathetic Denervation and Daily Life Blood Pressure in Resistant Hypertension: Simplicity or Complexity? Circulation. 2013;128:315–7.PubMedCrossRef
23.
de Souza F, Muxfeldt ES, Salles GF. Prognostic Factors in Resistant Hypertension: Implications for Cardiovascular Risk Stratification and Therapeutic Management. Expert Rev Cardiovasc Ther. 2012;10:735–45.PubMedCrossRef
24.
Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the Electrocardiographic Strain Pattern in Patients with Resistant Hypertension. Hypertension. 2006;48:437–42.PubMedCrossRef
25.
Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant Hypertension and Left Ventricular Hypertrophy: An Overview. J Am Soc Hypertens. 2010;4:319–24.PubMedCrossRef
26.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification. Eur J Echocardiogr. 2006;7:79–108.PubMedCrossRef
27.
Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients. Hypertension. 2004;43:731–8.PubMedCrossRef
28.
Cuspidi C, Giudici V, Negri F, Sala C, Mancia G. Left Ventricular Geometry, Ambulatory Blood Pressure and Extra-Cardiac Organ Damage in Untreated Essential Hypertension. Blood Press Monit. 2010;15:124–31.PubMedCrossRef
29.
Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of Left Ventricular Hypertrophy with Systemic Inflammation and Endothelial Damage in Resistant Hypertension. Hypertension. 2007;50:723–8.PubMedCrossRef
30.••
Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic Impact of Baseline and Serial Changes in ECG Left Ventricular Hypertrophy in Resistant Hypertension. Am Heart J. 2010;159:833–40. The prognostic importance of baseline and serial changes of left ventricular hypertrophy diagnosed by ECG. Treatment targeted at regression/prevention of LVH may improve cardiovascular prognosis.PubMedCrossRef
31.••
de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical Features of 8295 Patients with Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension. 2011;57:898–902. Based on Spanish Ambulatory Blood Pressure Monitoring Registry, this study estimated the prevalence of RHT (12.2%) and showed that true RHT is associated with a worse risk profile.PubMedCrossRef
32.
Salles G, Leocádio S, Bloch K, Nogueira AR, Muxfeldt E. Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension. Hypertension. 2005;46:1207–12.PubMedCrossRef
33.
Salles GF, Cardoso CR, Muxfeldt ES. Prognostic Value of Ventricular Repolarization Prolongation in Resistant Hypertension: A Prospective Cohort Study. J Hypertens. 2009;27:1094–101.PubMedCrossRef
34.
Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic Significance of Baseline and Serial Changes in ECG Strain Pattern in Resistant Hypertension. J Hypertens. 2010;28:1715–23.PubMedCrossRef
35.
Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, et al. Prognostic Significance of Left Ventricular Diastolic Dysfunction in Essential Hypertension. J Am Coll Cardiol. 2002;39:2005–11.PubMedCrossRef
36.
Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients with Resistant Hypertension and Hyperaldosteronism: A Prospective Clinical Study. Hypertension. 2010;55:1137–42.PubMedCentralPubMedCrossRef
37.
Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, et al. Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. J Clin Endocrinol Metab. 2011;96:2813–20.PubMedCentralPubMedCrossRef
38.
Schmieder RE. The Role of non-Haemodynamic Factors of the Genesis of LVH. Nephrol Dial Transplant. 2005;20:2610–2.PubMedCrossRef
39.
Muxfeldt ES, Cardoso CRL, Salles GF. Prognostic Value of Nocturnal Blood Pressure Reduction in Resistant Hypertension. Arch Intern Med. 2009;169:874–80.PubMedCrossRef
40.
Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and Outcomes of Resistant Hypertension Among Patients with Coronary Artery Disease and Hypertension. J Hypertens. 2014;32:635–43.PubMedCrossRef
41.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. INVEST Investigators. A Calcium Antagonist vs a non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): a Randomized Controlled Trial. JAMA. 2003;290:2805–16.PubMedCrossRef
42.
Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, et al. Treating to New Targets Steering Committee and Investigators. Prevalence, Predictors, and Outcomes in Treatment-Resistant Hypertension in Patients with Coronary Disease. Am J Med. 2014;127:71–81.PubMedCrossRef
43.
Faraco G, Iadecola C. Hypertension: A Harbinger of Stroke and Dementia. Hypertension. 2013;62:810–7.PubMedCrossRef
44.
Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline Values but not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients: Findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120:1084–90.PubMedCrossRef
45.
Schmieder RE, Schmidt BM, Raff U, Bramlage P, Dörfler A, Achenbach S, et al. Cerebral Microangiopathy in Treatment-Resistant Hypertension. J Clin Hypertens. 2011;13:582–7.CrossRef
46.
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of Cardiovascular Events and all-Cause Mortality with Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2010;55:1318–27.PubMedCrossRef
47.
Castelpoggi CH, Pereira VS, Fiszman R, Cardoso CRL, Muxfeldt ES, Salles G. A Blunted Decrease in Nocturnal Blood Pressure is Independently Associated with Increased Aortic Stiffness in Patients with Resistant Hypertension. Hypertens Res. 2009;32:591–6.PubMedCrossRef
48.
Muxfeldt ES, de Souza F, Salles GF. Resistant Hypertension: A Practical Clinical Approach. J Hum Hypert. 2013;27:657–2.CrossRef
49.••
Salles GF, Cardoso CRL, Fiszman R, Muxfeldt ES. Prognostic Importance of Baseline and Serial Changes in Microalbuminuria in Patients with Resistant Hypertension. Atherosclerosis. 2011;216:199–204. Baseline microalbuminuria is an important predictor of cardiovascular morbidity and mortality and microalbuminuria regression may be a antihypertensive treatment target.PubMedCrossRef
50.
Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. True Resistant Hypertension: Is it Possible to be Recognized in the Office? Am J Hypert. 2005;18:1534–40.CrossRef
51.
Oliveras A, Armario P, Martell-Clarós N, Ruilope LM, de la Sierra A, Spanish Society of Hypertension-Resistant Hypertension Registry. Urinary Albumin Excretion Is Associated with Nocturnal Systolic Blood Pressure in Resistant Hypertensives. Hypertension. 2011;57:556–60.PubMedCrossRef
52.••
Oliveras A, Armario P, Sierra C, Arroyo JA, Hernández-del-Rey R, Vazquez S, et al. Urinary Albumin Excretion at Follow-up Predicts Cardiovascular Outcomes in Subjects with Resistant Hypertension. Am J Hypertension. 2013;26:1148–54. Inability to regression, persistence and new appearance of urinary albumin excretion were associated with non-fatal cardiovascular events and death, whereas baseline albuminuria had no prognostic value.CrossRef
53.
Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects with Resistant Hypertension. Hypertension. 2008;51:339–44.PubMedCrossRef
54.
55.••
Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic Significance of a Reduced Glomerular Filtration Rate and Interaction with Microalbuminuria in Resistant Hypertension: A Cohort Study. J Hypertens. 2011;29:2014–23. Reduced glomerular filtration rate combined with increased albuminuria identifies a very high cardiovascular risk in patients with RHT.PubMedCrossRef
56.
Drexler YR, Bomback AS. Definition, Identification and Treatment of Resistant Hypertension in Chronic Kidney Disease Patients. Nephrol Dial Transplant 2013 (Epub ahead of print).
Metadata
Title
Cardiovascular and Renal Complications in Patients with Resistant Hypertension
Authors
Elizabeth S. Muxfeldt
Fabio de Souza
Victor S. Margallo
Gil F. Salles
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 9/2014
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0471-7

Other articles of this Issue 9/2014

Current Hypertension Reports 9/2014 Go to the issue

Blood Pressure Monitoring and Management (G Ogedegbe and JA Staessen, Section Editors)

Cardiovascular Risk Stratification and Blood Pressure Variability on Ambulatory and Home Blood Pressure Measurement

Preeclampsia (VD Garovic, Section Editor)

Treatment of Preeclampsia: Current Approach and Future Perspectives

Preeclampsia (VD Garovic, Section Editor)

How Does Preeclampsia Predispose to Future Cardiovascular Disease?

Blood Pressure Monitoring and Management (G Ogedegbe and JA Staessen, Section Editors)

The Complexity of Masked Hypertension: Diagnostic and Management Challenges

Preeclampsia (VD Garovic, Section Editor)

Maternal Preeclampsia and Risk for Cardiovascular Disease in Offspring

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

New Insights into Carbonic Anhydrase Inhibition, Vasodilation, and Treatment of Hypertensive-Related Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits